바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev
e-Submission

Vol.83 No.3
Citation Share

Prophylaxis of Venous Thromboembolism in Patients with Infectious Disease

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2020, v.83 no.3, pp.255-256
https://doi.org/10.4046/trd.2020.0029
Hun-Gyu Hwang (Soonchunhyang University)



Sam Schulman (McMaster University)
Hun-Gyu, H. , & Sam, S. (2020). Prophylaxis of Venous Thromboembolism in Patients with Infectious Disease. Tuberculosis & Respiratory Diseases, 83(3), 255-256, https://doi.org/10.4046/trd.2020.0029
  • Downloaded
  • Viewed
PDF Download

Abstract

keywords

Reference

1.

1. Dobromirski M, Cohen AT. How I manage venous thromboembolism risk in hospitalized medical patients. Blood 2012;120:1562-9.

2.

2. Jang MJ, Bang SM, Oh D. Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost 2011;9:85-91.

3.

3. Hwang HG, Choi WI, Lee B, Lee CW. Incidence and risk factors of recurrent venous thromboembolism after pulmonary embolism. Tuberc Respir Dis 2019;82:341-7.

4.

4. Hwang HG, Schulman S. Respiratory review of 2013: pulmonary thromboembolism. Tuberc Respir Dis 2013;75:89-94.

5.

5. Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost 2010;8:2105-12.

6.

6. Kim H, Jeon B. Developing a framework for performance assessment of the public long-term care system in Korea:methodological and policy lessons. Health Res Policy Syst 2020;18:27.

7.

7. Kim YK. Predictors of recurrent venous thromboembolism after pulmonary embolism in Korea. Tuberc Respir Dis 2019;82:357-8.

8.

8. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004;164:963-8.

9.

9. Clayton TC, Gaskin M, Meade TW. Recent respiratory infection and risk of venous thromboembolism: case-control study through a general practice database. Int J Epidemiol 2011;40:819-27.

10.

10. Lee GD, Ju S, Kim JY, Kim TH, Yoo JW, Lee SJ, et al. Risk factor and mortality in patients with pulmonary embolism combined with infectious disease. Tuberc Respir Dis 2020;83:157-66.

11.

11. Cohen AT, Spiro TE, Buller HR, Haskell L, Hu D, Hull R, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013;368:513-23.

12.

12. Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, et al. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med 2018;379:1118-27.

13.

13. Alikhan R, Peters F, Wilmott R, Cohen AT. Fatal pulmonary embolism in hospitalised patients: a necropsy review. J Clin Pathol 2004;57:1254-7.

14.

14. Cohen AT, Edmondson RA, Phillips MJ, Ward VP, Kakkar VV. The changing pattern of venous thromboembolic disease. Haemostasis 1996;26:65-71.

15.

15. Mahlab-Guri K, Otman MS, Replianski N, Rosenberg-Bezalel S, Rabinovich I, Sthoeger Z. Venous thromboembolism prophylaxis in patients hospitalized in medical wards: a real life experience. Medicine (Baltimore) 2020;99:e19127.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy